CNS PHARMACEUTICALS INC (CNSP) Stock Price & Overview
NASDAQ:CNSP • US18978H5081
Current stock price
The current stock price of CNSP is 2.51 USD. Today CNSP is up by 15.14%. In the past month the price increased by 2.87%. In the past year, price decreased by -74.49%.
CNSP Key Statistics
- Market Cap
- 2.033M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -486,000.00
- Dividend Yield
- N/A
CNSP Stock Performance
CNSP Stock Chart
CNSP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CNSP. When comparing the yearly performance of all stocks, CNSP is a bad performer in the overall market: 98% of all stocks are doing better.
CNSP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CNSP. CNSP may be in some trouble as it scores bad on both profitability and health.
CNSP Earnings
CNSP Forecast & Estimates
8 analysts have analysed CNSP and the average price target is 47.94 USD. This implies a price increase of 1809.96% is expected in the next year compared to the current price of 2.51.
CNSP Groups
Sector & Classification
CNSP Financial Highlights
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -486000. The EPS increased by 5.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -183.81% | ||
| ROE | -350.48% | ||
| Debt/Equity | 0.07 |
CNSP Ownership
CNSP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.59 | 878.257B | ||
| JNJ | JOHNSON & JOHNSON | 20.42 | 573.153B | ||
| MRK | MERCK & CO. INC. | 23.6 | 297.058B | ||
| PFE | PFIZER INC | 9.15 | 155.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 118.543B | ||
| ZTS | ZOETIS INC | 16.98 | 50.689B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.37 | 27.937B | ||
| VTRS | VIATRIS INC | 5.55 | 16.104B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.68 | 11.863B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.122B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.497B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.072B | ||
| CORT | CORCEPT THERAPEUTICS INC | 79.8 | 4.606B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNSP
Company Profile
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Company Info
IPO: 2019-11-08
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 5
Phone: 18009469185
CNS PHARMACEUTICALS INC / CNSP FAQ
What does CNSP do?
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
What is the current price of CNSP stock?
The current stock price of CNSP is 2.51 USD. The price increased by 15.14% in the last trading session.
Does CNSP stock pay dividends?
CNSP does not pay a dividend.
What is the ChartMill technical and fundamental rating of CNSP stock?
CNSP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for CNS PHARMACEUTICALS INC?
CNS PHARMACEUTICALS INC (CNSP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Short Interest ratio of CNS PHARMACEUTICALS INC (CNSP) stock?
The outstanding short interest for CNS PHARMACEUTICALS INC (CNSP) is 6.67% of its float.